Helus Pharma shares are trading higher after the company announced publication in Nature Medicine of results from a Phase 2a clinical trial evaluating SPL026, in major depressive disorder.

Cybin, Inc. +0.73% Post

Cybin, Inc.

HELP

5.50

5.51

+0.73%

+0.18% Post
Helus Pharma shares are trading higher after the company announced publication in Nature Medicine of results from a Phase 2a clinical trial evaluating SPL026, in major depressive disorder.